Inzucchi SE, Majumdar SK. Current therapies for the medical management of diabetes. Obstet Gynecol. 2016. https://doi.org/10.1097/AOG.0000000000001332.
Sattar N, Petrie MC, Zinman B, Januzzi JL. Novel diabetes drugs and the cardiovascular specialist. J Am Coll Cardiol. 2017. https://doi.org/10.1016/j.jacc.2017.04.014.
Sharma A, Cooper LB, Fiuzat M, Mentz RJ, Ferreira JP, Butler J, et al. Antihyperglycemic therapies to treat patients with heart failure and diabetes mellitus. JACC Hear Fail. 2018. https://doi.org/10.1016/j.jchf.2018.05.020.
Diamant M, Heine RJ. Thiazolidinediones in type 2 diabetes mellitus. Drugs. 2012;2003:6313. https://doi.org/10.2165/00003495-200363130-00004.
Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract. 2009. https://doi.org/10.1111/j.1742-1241.2008.01933.
Fass AD, Gershman JA. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin. Adv Ther. 2013. https://doi.org/10.1007/s12325-013-0023-6.
Saenz A, Fernandez-Esteban I, Mataix A, Segura MA, Roqué i Figuls M, Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005. https://doi.org/10.1002/14651858.CD002966.
Douros A, Lix LM, Fralick M, Dell’Aniello S, Shah BR, Ronksley PE, et al. Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis : a multicenter cohort study. Ann Intern Med. 2020. https://doi.org/10.7326/M20-0289.
Feingold KR. Oral and Injectable (Non-insulin) Pharmacological agents for type 2 diabetes. Endotext. MDText.com, Inc. 2000; PUBMED:25905364
Snyder MJ, Gibbs LM, Lindsay TJ. Treating painful diabetic peripheral neuropathy: an update. Am Fam Physician. 2016;PMID: 27479625
Lenox RH, Frazer A. Mechanism of action of antidepressants and mood stabilizers. Neuropsychopharmacol Fifth Gener Prog. 2002.
Shouip Hossam A. Tramadol synthesis and mechanism of action. Fac Pharm Pharm Ind Univ. 2015.
Bezchlibnyk-Butler K, Aleksic I, Kennedy SH. Citalopram--a review of pharmacological and clinical effects. J Psychiatry Neurosci. Canadian Medical Association. 2000. PMCID:PMC1407724, PMID: 10863884
Gopal L, Sharma T. Use of intravitreal injection of triamcinolone acetonide in the treatment of age-related macular degeneration. Indian J Ophthalmol. 2007. https://doi.org/10.4103/0301-4738.36477.
Chang-Lin JE, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann BD, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Investig Ophthalmol Vis Sci. 2011;10.1167 /iovs.10–5285
Taugourdeau-Raymond S, Rouby F, Default A, Jean-Pastor MJ. Bevacizumab-induced serious side-effects: a review of the French pharmacovigilance database. Eur J Clin Pharmacol. 2012. https://doi.org/10.1007/s00228-012-1232-7.
Muqit MMK, Sanghvi C, McLauchlan R, Delgado C, Young LB, Charles SJ, et al. Study of clinical applications and safety for Pascal® laser photocoagulation in retinal vascular disorders. Acta Ophthalmol. 2012. https://doi.org/10.1111/j.1755-3768.2009.01854.
Gawȩcki M. Micropulse laser treatment of retinal diseases. J Clin Med. 2019. https://doi.org/10.3390/jcm8020242.
Lim AKH. Diabetic nephropathy – complications and treatment. Int J Nephrol Renovasc Dis. 2014. https://doi.org/10.2147/IJNRD.S40172.
Shafiq MM, Menon DV, Victor RG. Oral direct renin inhibition: premise, promise, and potential limitations of a new class of antihypertensive drug. Am J Med. 2008. https://doi.org/10.1016/J.AMJMED.2007.11.016.
Bansal D, Badhan Y, Gudala K, Schifano F. Ruboxistaurin for the treatment of diabetic peripheral neuropathy: a systematic review of randomized clinical trials. Diabetes Metab J. 2013. https://doi.org/10.4093/dmj.2013.37.5.375.
Javey G, Schwartz SG, Flynn HW, Aiello LP, Sheetz MJ. Ruboxistaurin: review of safety and efficacy in the treatment of diabetic retinopathy. Clin Med Insights Ther. 2010. https://doi.org/10.4137/cmt.s5046.
Schemmel KE, Padiyara RS, D’Souza JJ. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review. J Diabetes Complications; 2010. http://dx.doi.org/10.1016/j.jdiacomp.2009.07.005.
Oak JH, Youn JY, Cai H. Aminoguanidine inhibits aortic hydrogen peroxide production, VSMC NOX activity and hypercontractility in diabetic mice. Cardiovasc Diabetol. 2009. https://doi.org/10.1186/1475-2840-8-65.
US7455830B2 - Nanoparticles for protein drug delivery. 2015.
RU02394590 - Application of local composition, containing epidermal growth factor (EGF), for prevention of amputation caused by diabetic foot. 2010.
CN103169719 - Application of anthracene nucleus antibiotic and its pharmaceutical salt for treating diabetic eye diseases. 2013.
IN718/CHE/2013 - Drug for treatment of diabetes and diabetic foot ulcer using rutin loaded solid lipid nanoparticles. 2014.
RU0002616525 - Application of lactoprotein micelles for babies with risk of obesity or diabetes. 2017.
JP6856546B2-Glucose-responsive insulin delivery system using hypoxia-sensitive nanocomposites. 2017.
Mohan S, Nandhakumar L. Role of various flavonoids: hypotheses on novel approach to treat diabetes. J Med Hypotheses Ideas . Tehran University of Medical Sciences; 2014. http://dx.doi.org/10.1016/j.jmhi.2013.06.001.
Tanveer A, Akram K, Farooq U, Hayat Z, Shafi A. Management of diabetic complications through fruit flavonoids as a natural remedy. Crit Rev Food Sci Nutr. 2017. http://dx.doi.org/10.1080/10408398.2014.1000482.
Chen J, Mangelinckx S, Adams A, Wang ZT, Li WL, De Kimpe N. Natural flavonoids as potential herbal medication for the treatment of diabetes mellitus and its complications. Nat Prod Commun. 2015. https://doi.org/10.1177/1934578x1501000140.
Joshi R, Kulkarni YA, Wairkar S. Pharmacokinetic, pharmacodynamic and formulations aspects of Naringenin: an update. Life Sci; 2018; https://doi.org/10.1016/j.lfs.2018.10.066.
Khajuria R, Singh S, Bahl A. General introduction and sources of flavonoids. Curr Asp Flavonoids Their Role Cancer Treat. 2019. https://doi.org/10.1007/978-981-13-5874-6-1.
Jucá MM, Cysne Filho FMS, de Almeida JC, Mesquita D da S, Barriga JR de M, Dias KCF, et al. Flavonoids: biological activities and therapeutic potential. Nat Prod Res. 2020; https://doi.org/10.1080/14786419.2018.1493588.
Agochukwu-Mmonu N, Pop-Busui R, Wessells H, Sarma AV. Autonomic neuropathy and urologic complications in diabetes. Auton Neurosci Basic Clin; 2020; https://doi.org/10.1016/j.autneu.2020.102736.
Sango K, Yamauchi J. Schwann cell development and pathology. Schwann Cell Dev Pathol. 2013. https://doi.org/10.1007/978-4-431-54764-8.
Obrosova IG. Update on the pathogenesis of diabetic neuropathy. Curr Diab Rep. 2003. https://doi.org/10.1007/s11892-003-0005-1.
Vincent AM, Russell JW, Low P, Feldman EL. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev. 2004. https://doi.org/10.1210/er.2003-0019.
Yagihashi S, Mizukami H, Sugimoto K. Mechanism of diabetic neuropathy: where are we now and where to go? J Diabetes Investig. 2011. https://doi.org/10.1111/j.2040-1124.2010.00070.
Muc R, Saracen A, Grabska-Liberek I. Associations of diabetic retinopathy with retinal neurodegeneration on the background of diabetes mellitus. Overview of recent medical studies with an assessment of the impact on healthcare systems. Open Med. 2018; https://doi.org/10.1515/med-2018-0008.
Schrepfer E, Scorrano L. Mitofusins, from mitochondria to metabolism. Mol Cell. 2016. https://doi.org/10.1016/j.molcel.2016.02.022.
Roy S, Kim D, Sankaramoorthy A. Mitochondrial structural changes in the pathogenesis of diabetic retinopathy. J Clin Med. 2019;8:1363. https://doi.org/10.3390/jcm8091363.
Pernas L, Scorrano L. Mito-Morphosis: mitochondrial fusion, fission, and cristae remodeling as key mediators of cellular function. Annu. Rev. Physiol. 2016. p. 505–31. https://doi.org/10.1146/annurev-physiol-021115-105011.
van der Bliek AM, Shen Q, Kawajiri S. Mechanisms of mitochondrial fission and fusion. Cold Spring Harb Perspect Biol . Cold Spring Harbor Laboratory Press. 2013; https://doi.org/10.1101/cshperspect.a011072.
Youle RJ, Van Der Bliek AM. Mitochondrial fission, fusion, and stress. Science (80-. ). American Association for the Advancement of Science; 2012. p. 1062–5. 10.1126/ science.1219855
Perico N, Benigni A, Remuzzi G. Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection . Nat. Rev. Drug Discov; 2008. p. 936–53. https://doi.org/10.1038/nrd2685.
Ruggenenti P, Cravedi P, Remuzzi G. The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol . Nature Publishing Group; 2010. https://doi.org/10.1038/nrneph.2010.58.
Cerutti PA, Trump BF. Inflammation and oxidative stress in carcinogenesis. Cancer Cells. 1991. https://doi.org/10.1007/978-1-4615-3520-1_75.
Kashihara N, Haruna Y, K Kondeti V, S Kanwar Y. Oxidative stress in diabetic nephropathy. Curr Med Chem. 2010. https://doi.org/10.2174/092986710793348581.
Angelova A, Rakotoarisoa M. Amphiphilic nanocarrier systems for curcumin delivery in neurodegenerative disorders. Medicines. 2018. https://doi.org/10.3390/medicines5040126.
Angelova A, Garamus VM, Angelov B, Tian Z, Li Y, Zou A. Advances in structural design of lipid-based nanoparticle carriers for delivery of macromolecular drugs, phytochemicals and anti-tumor agents. Adv Colloid Interface Sci . Elsevier B.V; 2017. http://dx.doi.org/10.1016/j.cis.2017.04.006.
Angelova A, Drechsler M, Garamus VM, Angelov B. Pep-Lipid Cubosomes and Vesicles Compartmentalized by micelles from self-assembly of multiple neuroprotective building blocks including a large peptide hormone PACAP-DHA. ChemNanoMat. 2019. https://doi.org/10.1002/cnma.201900468.
Angelova A, Angelov B. Dual and multi-drug delivery nanoparticles towards neuronal survival and synaptic repair. Neural Regen Res. 2017. https://doi.org/10.4103/1673-5374.208546.
Maherani B, Arab-Tehrany E, R Mozafari M, Gaiani C, Linder M. Liposomes: a review of manufacturing techniques and targeting strategies. Curr Nanosci. 2011 http://dx.doi.org/10.2174/157341311795542453.
Anderluzzi G, Lou G, Su Y, Perrie Y. Scalable manufacturing processes for solid lipid nanoparticles. Pharm Nanotechnol. 2019. https://doi.org/10.2174/2211738507666190925112942.
Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: structure preparation and application. Adv. Pharm. Bull. 2015. p. 305–13. http://dx.doi.org/10.15171/apb.2015.043.
Aguilar ZP. Types of nanomaterials and corresponding methods of synthesis. Nanomater Med Appl. 2013. https://doi.org/10.1016/B978-0-12-385089-8.00002-9.
Woodhead JL, Hall CK. Encapsulation efficiency and micellar structure of solute-carrying block copolymer nanoparticles. Macromolecules. 2011. https://doi.org/10.1021/ma102938g.
Singh J, Mittal P, Vasant Bonde G, Ajmal G, Mishra B. Design, optimization, characterization and in-vivo evaluation of Quercetin enveloped Soluplus®/P407 micelles in diabetes treatment. Artif Cells, Nanomedicine Biotechnol. 2018; https://doi.org/10.1080/21691401.2018.1501379.
Zielinska A, Carreiró F, Oliveira AM, Neves A, Pires B, Nagasamy Venkatesh D, et al. Polymeric nanoparticles: production, characterization, toxicology and ecotoxicology. Molecules. 2020. https://doi.org/10.3390/molecules25163731.
Wang Y, Li P, Tran TTD, Zhang J, Kong L. Manufacturing techniques and surface engineering of polymer based nanoparticles for targeted drug delivery to cancer. Nanomaterials. 2016. https://doi.org/10.3390/nano6020026.
Kittler S, Greulich C, Diendorf J, Köller M, Epple M. Toxicity of silver nanoparticles increases during storage because of slow dissolution under release of silver ions. Chem Mater American Chemical Society. 2010. https://doi.org/10.1021/cm100023p.
Zhao J, Yang J, Xie Y. Improvement strategies for the oral bioavailability of poorly water-soluble flavonoids: an overview. Int J Pharm. 2019. https://doi.org/10.1016/j.ijpharm.2019.118642.
Shi GJ, Li Y, Cao QH, Wu HX, Tang XY, Gao XH, et al. In vitro and in vivo evidence that quercetin protects against diabetes and its complications: a systematic review of the literature. Biomed Pharmacother. 2019. https://doi.org/10.1016/j.biopha.2018.10.130.
Alam MM, Abdullah KM, Singh BR, Naqvi AH, Naseem I. Ameliorative effect of quercetin nanorods on diabetic mice: mechanistic and therapeutic strategies. RSC Adv Royal Soc Chem. 2016. http://dx.doi.org/10.1039/C6RA04821H.
Ebrahimpour S, Esmaeili A, Beheshti S. Effect of quercetin-conjugated superparamagnetic iron oxide nanoparticles on diabetes-induced learning and memory impairment in rats. Int J Nanomedicine. 2018. https://doi.org/10.2147/IJN.S177871.
Mukhopadhyay P, Prajapati AK. Quercetin in antidiabetic research and strategies for improved quercetin bioavailability using polymer-based carriers-a review. RSC Adv Royal Sociry. 2015. https://doi.org/10.1039/C5RA18896B.
Chitkara D, Nikalaje SK, Mittal A, Chand M, Kumar N. Development of quercetin nanoformulation and in vivo evaluation using streptozotocin-induced diabetic rat model. Drug Deliv Transl Res. 2012. https://doi.org/10.1007/s13346-012-0063-5.
Wang S, Du S, Wang W, Zhang F. Therapeutic investigation of quercetin nanomedicine in a zebrafish model of diabetic retinopathy. Biomed Pharmacother. 2020. https://doi.org/10.1016/j.biopha.2020.110573.
Rishitha N, Muthuraman A. Therapeutic evaluation of solid lipid nanoparticle of quercetin in pentylenetetrazole induced cognitive impairment of zebrafish. Life Sci. Pergamon; 2018; https://doi.org/10.1016/J.LFS.2018.03.010.
Singh S, Kushwah V, Agrawal AK, Jain S. Insulin- and quercetin-loaded liquid crystalline nanoparticles: implications on oral bioavailability, antidiabetic and antioxidant efficacy. Nanomedicine. 2018. https://doi.org/10.2217/nnm-2017-0278.
留言 (0)